Research published in the European Journal of Epidemiology by Costanzo S, Di Castelnuovo de Gaetano G et al has sought to separate the effects of wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events. The Italian authors carried out an updated meta-analysis on the relationship between wine, beer or spirit consumption and cardiovascular outcomes, using state-of-the-art statistical techniques. From 16 studies, results confirmed a J-shaped relationship between wine intake and reduced vascular risk, with maximal protection - an average 31% (95% confidence interval (CI): 19%) was observed at 21 g/day of alcohol. Similarly, from 13 studies a J-shaped relationship was apparent for beer (maximal protection: 42% (95% CI: 19%) at 43 g/day of alcohol). From 12 studies reporting separate data on wine or beer consumption, two closely overlapping dose-response curves were obtained suggesting maximal protection of 33% at 25 g/day of alcohol approximately (2 drinks/day by US standards and 3 units for the UK) for vascular diseases.
According to an investigation in the November 23/30 issue of JAMA, approximately two-thirds of individuals with heart failure and infective endocarditis receive valvular surgery, which is associated with a considerable reduction in the risk of death in hospital and at one year following surgery. Infective endocarditis is an infection of the heart lining which may involve the heart valves. Background information in the report states: "Infective endocarditis is associated with substantial morbidity and mortality. Several published studies have reported in-hospital mortality of 15 percent to 20 percent and 1-year mortality of 40 percent. In the United States alone, approximately 15, 000 new cases of infective endocarditis are diagnosed each year. A variety of complications contribute to the high rates of morbidity and mortality in infective endocarditis, particularly heart failure (HF), which occurs in approximately 40 percent of patients.
According to a report published Online First by The Lancet, individuals admitted to hospital for an autoimmune disorder have a significantly higher risk of experiencing a pulmonary embolism during the next 12 months. Therefore prophylaxis may be permitted in these individuals. The article was written by Dr Bengt ZĂ ller, Center for Primary Health Care Research, Lund University and Clinical Research Centre, Malmo University Hospital, Sweden, and colleagues. Venous thromboembolism is a major health problem, for which pulmonary embolism is a potentially life threatening complication. Pulmonary embolism is a prevalent cardiovascular and cardiopulmonary disease. Each year in the U.S. more than 1 in 1, 000 individuals are affected by the illness, which has a morality rate of over 15% in the first three months after diagnosis, similar to the mortality rate for acute myocardial infarction ( heart attack ).
Only a few decades ago, sudden cardiac arrest was a death sentence. Today, a victim of sudden cardiac arrest is saved roughly once every six hours in Sweden, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden, reviewing all cases of sudden cardiac arrest over a 30-year period. Recent decades have brought enormous advances in the treatment of victims of sudden cardiac arrest, shows a thesis from the University of Gothenburg's Sahlgrenska Academy which looks at 3, 871 cases in Gothenburg both inside and outside hospital between 1980 and 2009. Unique study The thesis, in which doctoral student and registered physician Martin Fredriksson investigates both how patients were dealt with and with what outcome, includes several different studies, including three articles providing the first systematic and in-depth analysis of cardiac arrest inside hospital in Sweden.
The first system able to repair a failed or problematic aortic endograft, called the Aptus EndoStapling System, which consists of a fabric tube used for repairing dangerously large aortic aneurysm has been approved for marketing by the U.S. Food and Drug Administration. The FDA's approval means that surgeons are provided with a minimal-invasive alternative for repairing aortic endografts (endovascular grafts) that are incorrectly positioned. An aortic aneurysm is a general term for any swelling of the aorta, which over time, can weaken and result in a life-threatening rupture. The endograft is inserted on the inside of the aorta and seals off the aneurysm, redirecting the blood. The Aptus EndoStapling System consists of a cassette of nickel-cobalt corkscrew-shaped staples that is loaded into a long, thin, tube-like delivery catheter, which is then inserted into an artery in the leg and directed through the arteries to the failed endograft.